The abstract is read at the publisher; the summary is JClub's.
Heart failure with reduced ejection fraction remains a major burden because contractile dysfunction is not corrected by GDMT, and conventional inotropes improve contractility but worsen outcomes.
- Why it matters: Guideline-directed medical therapy slows progression via neurohormonal modulation yet leaves the core deficit in contractile function, especially in advanced HFrEF, insufficiently addressed.
- What they did: This review synthesizes pathophysiologic mechanisms of impaired contractility in HFrEF and therapeutic strategies that enhance contractility, covering both calcium-dependent inotropes and emerging small-molecule classes, with preclinical and clinical evidence.
- The result: Novel approaches are described as enhancing cardiac contractility without the deleterious effects of conventional inotropes, suggesting a shift toward direct myocardial modulation for acute and chronic HF.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.